Improve Access to Biomarker Testing 

With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early stages, early detection and diagnosis are even more critical to ensure individuals receive the most benefit at the earliest point possible. Biomarkers offer one of the most promising paths to improve dementia detection, diagnosis and treatment. Yet these critical tests remain out of reach for many as insurance coverage is failing to keep pace with innovations and advancements in treatments. The Alzheimer’s Association is urging state lawmakers to expand insurance coverage of comprehensive biomarker testing. Without this legislation, dementia diagnoses may take up to two years, increasing the long-term costs to the individual, family and the state.

Increase Respite Funding to Project C.A.R.E

More than 381,000 dementia caregivers in North Carolina provided 739 million hours in unpaid care in 2025, often enabling their loved ones living with dementia to live in the community instead of moving into more costly residential long-term care. Current state funding is inadequate to meet the existing needs of dementia caregivers, and this shortfall will only grow as the dementia population continues to increase in North Carolina. The Alzheimer’s Association is calling on state lawmakers to increase funding to $2 million for the state’s only dementia-specific respite program, Project C.A.R.E. This funding increase will allow the program to expand by adding additional host sites and respite care grants for caregivers.